Hepatobiliary cancers, version 1.2017 featured updates to the NCCN guidelines

Al B. Benson, Michael I. D'Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel Anaya Saenz, Chandrakanth Are, Daniel B. Brown, Daniel T. Chang, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey SchefterCarl Schmidt, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean Nicolas Vauthey, Alan P. Venook, Andrew X. Zhu, Karin G. Hoffmann, Susan Darlow

Research output: Contribution to journalReview articlepeer-review

269 Scopus citations

Abstract

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.

Original languageEnglish (US)
Pages (from-to)563-573
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number5
DOIs
StatePublished - May 1 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Hepatobiliary cancers, version 1.2017 featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this